FrancophonIA/ELRC3.0 huggingface dataset:
English: Luxembourg BAYER SA-NV Avenue Louise 143
Maltese: Il-Lussemburgu BAYER SA-NV Avenue Louise 143
English: 10 to 21 days
Maltese: 10 sa 21 ġurnata
English: The response document included a review of clinical data (published data, medical research reports) and microbiological data.
Maltese: Id-dokument ta' reazzjoni inkluda reviżjoni ta' dejta klinika (dejta, rapporti ta' riċerka medika ppubblikati) u dejta mikrobijoloġika.
English: • caffeine
Maltese: • kafeina
English: Ventricular arrhythmia, QT prolongation, torsades de pointes *
Maltese: Arritmija ventrikulari , titwil talQT, torsades de pointes *
English: COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1)
Maltese: B'MOD KOMUNI Mikro-organiżmi aerobiċi Gram-positive Bacillus anthracis (1)
English: Aerobic Gram-negative micro-organisms Acinetobacter baumannii+
Maltese: Mikro-organiżmi aerobiċi Gram-negative Acinetobacter baumannii+
English: -Diarrhoea caused by bacterial pathogens including Shigella spp.
Maltese: -Dijarrea ikkaġunata minn patoġeni batteriċi inklużi Shigella spp.
English: other than Shigella dysenteria type 1and empirical treatment of traveller's diarrhoea (per os : 2 x 500 mg/d - 1 day, i.v : 2 x 400 mg/d - 1 day) -Diarrhoea caused by Shigella dysenteriae type 1 (per os : 2 x 500 mg/d - 5 days, i.v : 2x400 mg/d- 5 days)
Maltese: Barra minn Shigella dysenteria tip 1 u trattament empiriku ta' dijarrea tal-vjaġġaturi (per os : 2 x 500 mg/kuljum - jum 1, i.v : 2 x 400 mg/kuljum - jum 1) - Dijarrea ikkaġunata minn Shigella dysenteriae tip 1 (per os : 2 x 500 mg/kuljum - 5 ijiem, i.v : 2x400 mg/kuljum - 5 ijiem)
English: Bayer Pharma, d.o.o., Bravničarjeva 13 SI-1000 Ljubljana Slovenia
Maltese: Bravničarjeva 13 SI-1000 Ljubljana Is-Slovenja
English: BAYER HELLAS ΑΒΕΕ 18-20 Sorou Street 15125 Marousi , Athens, Greece
Maltese: BAYER HELLAS ΑΒΕΕ 18-20 Sorou Street 15125
English: • probenecid (for gout)
Maltese: probenecid (għall-gotta)
English: Prostatitis
Maltese: Prostatite
English: • pentoxifylline (for circulatory disorders)
Maltese: • pentoxifylline (għal disturbi fiċ-ċirkulazzjoni)
English: 124 to 168 200-400 mg every 12 h 200-400 mg every 24 h
Maltese: 124 to 168 200-400 mg kull 12 h 200-400 mg kull 24 h
English: Depression Hallucinations
Maltese: Depressjoni Alluċinazzjonijiet
English: Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (Cmax) between 0.56 and 3.7 mg/L.
Maltese: Dożi waħedhom ta' 100-750 mg ipproduċew konċentrazzjonijiet massimi fis-serum (Cmax) bejn 0.56 u 3.7 mg/L dipendenti mid-doża.
English: Spectrum of antibacterial activity:
Maltese: Firxa ta' l-attività antibatterika:
English: Diarrhoea caused by Vibrio cholerae
Maltese: Dijarea kkawżata minn Vibrio cholerae
English: The applicant/MAH submitted 11 studies (8 published clinical studies and 3 medical study reports) in which treatment duration for ciprofloxacin ranged from 2 and 476 days.
Maltese: L-applikant/MAH issottometta 11-il studju (8 studji kliniċi ppubblikati u 3 rapporti ta' studji mediċi) għal liema t-tul ta' żmien ta' trattament għal ciprofloxacin varja minn jumejn sa 476 jum.
English: Other xanthine derivatives
Maltese: Derivattivi oħra ta' xanthine
English: In its original document the applicant/MAH proposed an oral posology of 500 mg QD and an IV posology of 200 mgx2.
Maltese: Fid-dokument oriġinali tiegħu l-applikant/MAH ippropona pożoloġija orali ta' 500 mg QD u pożoloġija IV ta' 200 mgx2.
English: Diarrhoea caused by Shigella dysenteriae type 1
Maltese: Dijarea kkawżata minn Shigella dysenteriae tip 1
English: In adult patients, infusion time is 60 minutes for 400 mg Ciprofloxacin Bayer and 30 minutes for 200 mg Ciprofloxacin Bayer.
Maltese: F'pazjenti adulti, il-ħin ta' l-infużjoni huwa 60 minuta għal 400 mg Ciprofloxacin Bayer u 30 minuta għal 200 mg Ciprofloxacin Bayer.
English: Rare ≥ 1/10 000 to <
Maltese: Rari ≥ 1/10 000 sa <
English: • taking tizanidine (see Section 2: Taking other medicines)
Maltese: • qed tieħu tizanidine (ara sezzjoni 2: Meta tieħu mediċini oħra)
English: Preparing and taking the suspension
Maltese: Preparazzjoni u teħid tas-suspensjoni
English: Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%.
Maltese: Rispettivament, l-inċidenza ta' artropatija relatata mal-mediċina mal-vista ta' wara sena kienet ta' 9.0% u 5.7%.
English: SPC Section 4.1 Therapeutic Indications
Maltese: SPC Sezzjoni 4.1 Indikazzjonijiet terapewtiċi
English: For children, the infusion duration is 60 minutes.
Maltese: Għat-tfal, it-tul ta' l-infużjoni huwa 60 minuta.
English: Listeria monocytogenes Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia
Maltese: Mikro-organiżmi aerobiċi Gram-negative Stenotrophomonas maltophilia
English: Aerobic Gram-negative micro-organisms Aeromonas spp.
Maltese: Mikro-organiżmi aerobiċi Gram-negative Aeromonas spp.
English: Ciprofloxacin Bayer is an antibiotic belonging to the fluoroquinolone family.
Maltese: Ciprofloxacin Bayer huwa antibijotiku li jagħmel parti mill-familja fluoroquinolone.
English: Complicated pyelonephritis
Maltese: Pijelonefrite komplikata
English: Diarrhoea caused by Shigella dysenteriae type
Maltese: Dijarea kkawżata minn Shigella dysenteriae tip
English: Interaction with tests
Maltese: Interazzjoni mat-testijiet
English: 5 to 14 days
Maltese: 5 sa 14-il ġurnata
English: Urine
Maltese: Urinarja
English: Do not pour water into the suspension!
Maltese: Tfergħax ilma ġewwa s-suspensjoni!
English: 28 days up to 3 months
Maltese: 28 ġurnata sa 3 xhur
English: Ciproxin oral suspension oral use
Maltese: SUSPENSJONI ORALI
English: Cystic fibrosis
Maltese: Fibrożi ċistika
English: It can also increase the probability of experiencing side effects.
Maltese: Jista' wkoll iżid il-probabbiltà li jkollok esperjenza ta' effetti sekondarji.
English: Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.
Maltese: Ciprofloxacin huwa magħruf li huwa inibitur moderat ta' iso-enżimi CYP 450 1A2.
English: Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively.
Maltese: Wara għoti ta' 250 mg ciprofloxacin flimkien ma' clozapine għal 7 ġranet, konċentrazzjonijiet fisserum ta' clozapine u N-desmethylclozapine żdiedu b'29% u 31%, rispettivament.
English: Psychotic reactions (see section 4.4)
Maltese: Reazzjonijiet psikotiċi (ara sezzjoni 4.4)
English: Most reported adverse events were not unexpected, mainly gastro-intestinal disorders or cutaneous disorders.
Maltese: Il-maġġoranza tal-episodji avversi rapportati kienu mistennija, prinċipalment disturbi gastro-intestinali jew disturbi tal-ġilda.
English: Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h.
Maltese: It-tneħħija renali hija bejn 180-300 mL/kg/h u t-tneħħija totali mill-ġisem hija bejn 480-600 mL/kg/h.
English: Vomiting, Transient increase in transaminases, Rash
Maltese: Rimettar, Żjieda temporanja fit-transaminases, Raxx
English: The pharmacokinetics of ciprofloxacin oral suspension 50 mg/mL and 100 mg/mL are similar to those of tablets.
Maltese: Il-farmakokinetika ta' ciprofloxacin 50 mg/mL u 100 mg/mL suspensjoni orali hija simili għal dik talpilloli.
English: 200-400 mg every 24 h
Maltese: 200-400 mg kull 24 h
English: Pharmacotherapeutic group: Fluoroquinolones, ATC code: J01MA02
Maltese: Kategorija farmakoterapewtika: Fluoroquinolones, Kodiċi ATC:
English: Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%.
Maltese: Tagħrif dwar is-sigurtà minn studju randomised double-blind dwar l-użu ta' ciprofloxacin fit-tfal (ciprofloxacin: n=335, età medja = 6.3 snin; komparaturi: n=349, età medja = 6.2 snin; firxa ta' l-età = 1 sa 17-il sena) wera inċidenza ta' artropatija suspettata relatata mal-mediċina (misjuba minn sinjali u sintomi kliniċi relatati mal-ġogi) mal-Ġurnata +42 ta' 7.2% u 4.6%.
English: Intra-abdominal infections
Maltese: Infezzjonijet intra-addominali
English: Burkholderia cepacia +* Campylobacter spp.+* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae * Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
Maltese: Burkholderia cepacia+* Campylobacter spp.+* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris*
English: Vasodilatation Hypotension Syncope
Maltese: Vasodilatazzjoni Pressjoni baxxa Sinkope
English: • Tell your doctor if you or a member of your family is known to have a deficiency in glucose-6phosphate dehydrogenase (G6PD), since you may experience a risk of anemia with ciprofloxacin.
Maltese: Għid lit-tabib tiegħek jekk huwa magħruf li inti jew membru fil-familja tiegħek għandkom defiċjenza ta' glucose-6-phosphate dehydrogenase (G6PD), peress li jista' jkollok esperjenza ta' riskju ta' anemija b'ciprofloxacin.
English: The following oral and intravenous formulations are currently approved and marketed in different EU countries: - Immediate release film-coated tablets: 100 mg, 250 mg, 500 mg, 750 mg - Granules and solvent for oral suspension: 250 mg/5 ml, 500 mg/5 ml - Solution for infusion (glass bottles and flexibags): 100 mg/50 ml, 200 mg/100 ml and 400 mg/200 ml - Modified release film-coated tablets: 500 mg, 1000 mg. - Sachets: 250mg, 500mg
Maltese: - Pilloli miksijin b'rita ta' rilaxx immedjat: 100 mg, 250 mg, 500 mg, 750 mg - Granuli u solvent għal sospensjoni orali: 250 mg/5 ml, 500 mg/5 ml - Soluzzjoni għall-infużjoni (fliexken tal-ħġieġ u boroż flessibbli): 100 mg/50 ml, 200 mg/100 ml u 400 mg/200 ml - Pilloli miksijin b'rita ta' rilaxx modifikat: 500 mg, 1000 mg.
English: • Epididymo-orchitis, including cases due to Neisseria gonorrhoeae
Maltese: • Epididimo-orkite, inklużi każijiet minn Neisseria gonorrhoeae
English: 250-500 mg every 24 h
Maltese: 250-500 mg kull 24 h
English: Withdrawn Indications
Maltese: Indikazzjonijet irtirati
English: The full spoon will give you a dose of 250 mg Ciprofloxacin Bayer.
Maltese: Mgħarfa mimlija tagħtik doża ta' 250 mg Ciprofloxacin Bayer.
English: Common ≥ 1/100 to <
Maltese: Komuni ≥ 1/100 sa <
English: Bayer Vital GmbH D-51368 Leverkusen Germany
Maltese: Bayer Vital GmbH D-51368 Leverkusen
English: 7 to 14 days
Maltese: 7 sa 14-il ġurnata
English: Renal failure Haematuria Crystalluria (see section 4.4) Tubulointerstitial nephritis
Maltese: Kristallurja (ara sezzjoni 4.4) Nefrite tubulointerstizjali
English: Psychomotor hyperactivity / agitation
Maltese: Attività eċċessiva psikomotorja / aġitazzjoni
English: The graduated measuring spoon with the markings 1/2 is equivalent to 2.6 mL containing 2.5 mL of final suspension and 1/1 is equivalent to 5.2 mL containing 5.0 mL of final suspension.
Maltese: Il-mgħarfa b'marki tal-kejl bil-marki 1/2 li hija ekwivalenti għal 2.6 mL u fiha 2.5 mL ta' suspensjoni finali u 1/1 li hija ekwivalenti għal 5.2 mL u fiha 5.0 mL ta' suspensjoni finali.
English: An acute overdose of 16 g has been reported to cause acute renal failure.
Maltese: Doża eċċessiva akuta ta' 16 g ġiet irrapportata li tikkawża insuffiċjenza akuta tal-kliewi.
English: Gastrointestinal System
Maltese: Sistema Gastro-intestinali
English: Reversible renal toxicity has been reported.
Maltese: Kienet irrapportata tossiċità renali riversibbli.
English: Iceland:
Maltese: L-Islanda:
English: • gastro-intestinal tract infections and intra-abdominal infections
Maltese: • infezzjonijiet fl-apparat gastro-intestinali u intra-addominali
English: The metabolites display in-vitro antimicrobial activity but to a lower degree than the parent compound.
Maltese: Il-metaboliti juru attività in-vitro kontra l-mikrobi iżda fi grad inqas missustanza oriġinali.
English: Ciprofloxacin has been shown to cause photosensitivity reactions.
Maltese: Ciprofloxacin intwera li jikkawża reazzjonijiet ta' fotosensittività.
English: • Intra-abdominal infections
Maltese: • Infezzjonijet intra-addominali
English: The full spoon will give you a dose of 500 mg Ciprofloxacin Bayer.
Maltese: Mgħarfa mimlija tagħtik doża ta' 500 mg Ciprofloxacin Bayer.
English: The pharmacokinetics of ciprofloxacin 250 mg and 500 mg oral suspension in single-dose sachets are similar to those of tablets.
Maltese: Il-farmakokinetika ta' ciprofloxacin 250 mg u 500 mg suspensjoni orali fi qratas b'doża waħda hija simili għal dik tal-pilloli.
English: • have myasthenia gravis (a type of muscle weakness)
Maltese: • għandek myasthenia gravis (tip ta' indebboliment muskolari)
English: • Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).
Maltese: • L-għoti flimkien ta' ciprofloxacin u tizanidine (ara sezzjoni 4.5).
English: PHARMACEUTICAL FORM Granules and solvent for oral suspension [To be completed nationally]
Maltese: GĦAMLA FARMAĊEWTIKA Grani u solvent għal suspensjoni orali [Biex timtela mill-pajjiż partikolari]
English: In a study in children Cmax and AUC were not age-dependent (above one year of age).
Maltese: Fi studju fit-tfal Cmax u AUC ma kienux dipendenti mill-età ('l fuq minn età ta' sena).
English: ($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance (1): Studies have been conducted in experimental animal infections due to inhalations of Bacillus anthracis spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose.
Maltese: ($): Suxxettibilità intermedja naturali fin-nuqqas ta' mekkaniżmu ta' reżistenza miksub (1): Twettqu studji dwar infezzjonijiet f'bhejjem sperimentali ikkawżati minn teħid man-nifs ta' spori ta' Bacillus anthracis; dawn l-istudji wrew li antibijotiċi mibdija kmieni wara lesponiment, jevitaw l-okkorrenza tal-marda jekk il-kura ssir għat-tnaqqis tan-numru ta' spori fl-organiżmu taħt id-doża infettiva.
English: It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of Cmax and AUC of ropinirole by 60% and 84%, respectively.
Maltese: Fi studju kliniku intwera li l-użu ta' ropinirole flimkien ma' ciprofloxacin, inibitur moderat ta' lisożima CYP450 1A2, iwassal għal żjieda f'Cmax u l-AUC ta' ropinirole ta' 60% u 84%, rispettivament.
English: 124 to 168 250-500 mg every 12 h 250-500 mg every 24 h
Maltese: 250-500 mg kull 12 h 250-500 mg kull 24 h
English: Central Nervous System
Maltese: Sistema Nervuż Ċentrali
English: Par- and Dysaesthesia Hypoaesthesia Tremor Seizures (see section 4.4) Vertigo
Maltese: Aċċessjonijiet (ara sezzjoni 4.4) Vertigo
English: Czech Republic: Ciprobay Denmark:
Maltese: Ir-Repubblika Ċeka: Ciprobay Id-Danimarka:
English: Haemolytic anaemia Agranulocyt osis
Maltese: Infezzjonijiet ta' lapparat ġenitali
English: Prophylaxis of invasive infections due to Neisseria meningitidis
Maltese: Profilassi ta' infezzjonijiet invażivi kkawżati minn Neisseria meningitidis
English: The serum elimination half-life in subjects with normal renal function is approximately 4-7 hours.
Maltese: Il-half-life tal-eliminazzjoni fis-serum f'individwi b'funzjoni renali normali hija madwar 4-7 sigħat.
English: Czech Republic Ciprobay France:
Maltese: Ir-Republika Ċeka: Ciprobay Franza:
English: Uncommon ≥ 1/1 000 to <
Maltese: Mhux Komuni ≥ 1/1 000 sa <
English: (2): Methicillin-resistant S. aureus very commonly express co-resistance to fluoroquinolones.
Maltese: (2): S. aureus reżistenti għal methicillin spiss ħafna ġeneralment juru reżistenza għal fluoroquinolones ukoll.
English: (pyelonephritis)
Maltese: (newtropenija)
English: CIPROBAY 10 g/100 ml oral suspension oral use
Maltese: CIPROBAY 10 g/100 ml suspensjoni orali użu orali
English: Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications + Resistance rate ≥ 50% in one or more EU countries
Maltese: Ureaplasma urealitycum * Effikaċja klinika ġiet dimostrata għal iżolati suxxettibli f'indikazzjonijiet kliniċi approvati + Rata ta' reżistenza ≥ 50 % f'wieħed jew aktar mill-pajjiżi ta' l-EU
English: Bulgaria:
Maltese: Il-Bulgarija:
English: Since ciprofloxacin is associated with cases of QT prolongation (see section 4.8), caution should be exercised when treating patients at risk for torsades de pointes arrhythmia.
Maltese: Peress li ciprofloxacin huwa assoċjat ma' każijiet ta' titwil fil-QT (ara sezzjoni 4.8), għandu jkun hemm kawtela meta jiġu kkurati pazjenti b'riskju ta' arritmija torsades de pointes.
English: 60 days from the confirmation of Bacillus anthracis exposure
Maltese: 60 ġurnata mill-konferma ta' esponiment għal Bacillus anthracis
English: Thrombocytopenia Thrombocytaemia
Maltese: Tromboċitopenija Tromboċitemija
English: The in-vitro activity of ciprofloxacin against Mycobacterium tuberculosis might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.
Maltese: L-attività in-vitro ta' ciprofloxacin kontra Mycobacterium tuberculosis tista' tagħti riżultati negattivi foloz tat-testijiet batterjoloġiċi f'kampjuni minn pazjenti li jkunu qed jieħdu ciprofloxacin.
English: Migraine Disturbed coordination Gait disturbance Olfactory nerve disorders Intracranial hypertension
Maltese: Emigranja Disturbi filkoordinazzjoni Disturb fil-mixja Disturbi fin-nerv tax-xamm Pressjoni intrakranjali għolja
English: Renal and urinary system
Maltese: Sistema renali u ta' l-awrina
English: Allergic reaction Allergic oedema / angiooedema
Maltese: Reazzjoni allerġika Edima allerġika /anġjoedima
English: Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance.
Maltese: Impermeabilità u/jew mekkaniżmi ta' reżistenza tal-pompa ta' effluss tas-sustanza attiva jista' jkollhom effett varjabbli fuq is-suxxettibilità għal fluoroquinolones, li tiddependi fuq il-karatteristiċi fisjokimiċi ta' diversi sustanzi attivi fil-klassi u l-affinità tas-sistemi ta' transport għal kull sustanza attiva.
English: Pancytopenia, Bone marrow depression, Anaphylactic shock, Psychotic reactions, Migraine, Olfactory nerve disorders, Hearing impaired, Vasculitis, Pancreatitis, Liver necrosis, Petechiae, Tendon rupture
Maltese: Panċitopenija, Depressjoni tal-mudullun ta' l-għadam, Xokk anafilattiku, Reazzjonijiet psikotiċi, Emigranja, Disturbi fix-xamm, Smigħ imnaqqas, Vaskulite, Pankreatite, Nekrosi tal-fwied, Petekja, Tiċrit tat-tendon
English: • Epididymo-orchitis including cases due to Neisseria gonorrhoeae
Maltese: • Epididimo-orkite inkluż każijiet ikkawżati minn Neisseria gonorrhoeae
English: Musculoskeletal, Connective Tissue and Bone Disorders
Maltese: Disturbi Muskoluskeltrali u talConnective Tissue
English: 250-500 mg every 24 h (after dialysis)
Maltese: 250-500 mg kull 24 h (wara dijalisi)
English: 200-400 mg every 24 h (after dialysis)
Maltese: 200-400 mg kull 24 h (wara dijalisi)
English: Effects of other products on ciprofloxacin:
Maltese: Effetti ta' prodotti oħra fuq ciprofloxacin:
English: Clinical trials have included children and adolescents aged 5-17 years.
Maltese: Provi kliniċi inkludew tfal u adoloxxenti b'età ta' 5-17-il sena.
English: • Prophylaxis of invasive infections due to Neisseria meningitidis
Maltese: • Profilassi ta' infezzjonijiet invażivi kkawżati minn Neisseria meningitidis
English: Excretion of ciprofloxacin (% of dose)
Maltese: Tneħħija ta' ciprofloxacin (% tad-doża)
English: 10 to 14 days
Maltese: 10 sa 14-il ġurnata
English: • Infections of the gastro-intestinal tract (e.g. travellers' diarrhoea)
Maltese: • Infezzjonijiet ta' l-apparat gastro-intestinali (e.ż. dijarea tal-vjaġġaturi)
English: Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.
Maltese: Funzjoni renali indebolita b'mod sever twassal għal żjieda fil-half-lives ta' ciprofloxacin sa 12 h.
English: Complicated cystitis, Uncomplicated pyelonephritis
Maltese: Ċistite komplikata, Pijelonefrite mhux komplikata
English: • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa.
Maltese: • Infezzjonijiet bronko-pulmonari f'fibrożi ċistika ikkaġunata minn Pseudomonas aeruginosa.
English: Aerobic Gram-positive micro-organisms
Maltese: Mikro-organiżmi aerobiċi Gram-positive
English: Eosinophilia Leukopenia Anaemia
Maltese: Esinofilja Lewkopenija Anemija
English: Broncho-pulmonary infections in cystic fibrosis
Maltese: Infezzjonijiet bronko-pulmonari f'fibrożi ċistika
English: 2 to 4 weeks (acute) to 4 to 6 weeks (chronic)
Maltese: 2 sa 4 ġimgħat (akuta) sa 4 sa 6 ġimgħat (kronika)
English: Petechiae Erythema multiforme Erythema nodosum StevensJohnson syndrome (potentially lifethreatening)
Maltese: Eritima multiforme Eritima nodosum Sindrome StevensJohnson (b'potenzjal ta' periklu għallħajja)
English: There have been many reports of increases in oral anti-coagulant activity in patients receiving antibacterial agents, including fluoroquinolones.
Maltese: Kien hemm ħafna rapporti ta' żjidiet fl-attività orali kontra l-koagulazzjoni f'pazjenti li kienu qed jirċievu sustanzi kontra l-batterja, inkluż fluoroquinolones.
English: Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)
Maltese: Kolite assoċjata ma' antibijotiċi (rari ħafna b'possibiltà ta' riżultat fatali) (ara sezzjoni 4.4)
English: Effects of other medicinal products on Ciprofloxacin:
Maltese: Effetti ta' prodotti mediċinali oħra fuq ciprofloxacin:
English: Patients on peritoneal dialysis
Maltese: Nekrolisi epidermika tossika
English: Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, ropinirole, tizanidine).
Maltese: Ciprofloxacin jinibixxi lil CYP1A2 u għalhekk jista' jikkawża żjieda fil-konċentrazzjoni fis-serum ta' sustanzi mogħtija fl-istess waqt metabolizzati minn din l-enżima (e.ż. theophylline, clozapine, ropinirole, tizanidine).
English: Consequently, the following wording was recommended in section 4.1, and subsequently section 4.2 was amended accordingly: - acute exacerbations of chronic sinusistis especially if these are caused by Gram-negative bacteria - gonococcal urethritis and cervicitis - epididymo-orchitis including cases due to Neisseria gonorrhoeae - pelvic inflammatory disease including cases due to Neisseria gonorrhoeae - malignant external otitis
Maltese: Konsegwentement, il-kitba li ġejja ġiet irrakkomandata fis-sezzjoni 4.1, u għalhekk, sussegwentement is-sezzjoni 4.2 ġiet emendata: - taħrixiet ta' sinożite kronika speċjalment jekk dawn huma kkaġunati minn batterji Gram negattivi - uretrite u ċerviċite gonokokkali - epididimo-orkite inklużi każijiet minħabba Neisseria gonorrhoeae - mard pelviku infjammatorju inklużi każijiet minħabba Neisseria gonorrhoeae - otite esterna malinna
English: Thrombocytopenia, Thrombocytaemia, Confusion and disorientation, Hallucinations, Par- and dysaesthesia, Seizures, Vertigo, Visual disturbances, Hearing loss, Tachycardia, Vasodilatation, Hypotension, Transient hepatic impairment, Cholestatic icterus, Renal failure, Oedema
Maltese: Tromboċitopenija, Tromboċitemija, Konfużjoni u diżorjentazzjoni, Alluċinazzjonijiet, Par- u disestesija, Aċċessjonijiet, Vertigo, Disturbi filvista, Telf ta' smigħ, Takikardija, Vasodilatazzjoni, Pressjoni baxxa, Indeboliment temporanju tal-fwied, Ikterus kolestatiku, Insuffiċjenza renali, Edima